PRQR
ProQR Therapeutics N.V

4,285
Loading...
Loading...
News
all
press releases
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +3.88% and +9.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $3.80
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) has been given a consensus rating of "Buy" by the four research firms that are covering the company, MarketBeat Ratings reports. Four investment...
Zolmax·2y ago
News Placeholder
Chardan Capital Boosts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.50
ProQR Therapeutics (NASDAQ:PRQR Get Free Report) had its target price lifted by Chardan Capital from $2.00 to $2.50 in a note issued to investors on Thursday, Benzinga reports. The brokerage...
Ticker Report·2y ago
News Placeholder
ProQR Therapeutics sees cash runway into mid-2026
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
ProQR Therapeutics reports 2023 EPS (EUR 0.35) vs. (EUR 0.90) last year
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
ProQR Announces Year End 2023 Operating and Financial Results
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further...
Globe Newswire·2y ago
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts
ProQR Therapeutics (NASDAQ:PRQR Get Free Report) has been assigned a consensus rating of Buy from the five research firms that are covering the company, Marketbeat Ratings...
Zolmax·2y ago
News Placeholder
ProQR Announces Japanese Axiomer Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies...
Globe Newswire·2y ago
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Buy at StockNews.com
ProQR Therapeutics (NASDAQ:PRQR Get Free Report) was upgraded by equities research analysts at StockNews.com from a hold rating to a buy rating in a report...
Zolmax·2y ago
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts
Shares of ProQR Therapeutics (NASDAQ:PRQR Get Free Report) have received a consensus recommendation of Buy from the five ratings firms that are covering the firm, Marketbeat...
Ticker Report·2y ago

Latest PRQR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.